Production (Stage)
Acrivon Therapeutics, Inc.
ACRV
$1.17
$0.021.74%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -19.68M | -22.83M | -22.44M | -18.80M | -16.49M |
| Total Depreciation and Amortization | 311.00K | 303.00K | 251.00K | 228.00K | 224.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.68M | 3.05M | 2.70M | 2.70M | 2.99M |
| Change in Net Operating Assets | -3.85M | 2.12M | 2.16M | 1.97M | -3.81M |
| Cash from Operations | -19.54M | -17.36M | -17.32M | -13.90M | -17.08M |
| Capital Expenditure | -58.00K | -827.00K | -989.00K | -137.00K | -815.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 19.27M | 15.24M | 17.00M | -87.91M | 6.67M |
| Cash from Investing | 19.21M | 14.41M | 16.01M | -88.04M | 5.85M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.00K | 0.00 | 0.00 | 70.01M | 79.00K |
| Repurchase of Common Stock | -344.00K | -647.00K | -1.20M | -510.00K | -166.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | -307.00K | 53.85M | -85.00K |
| Cash from Financing | -343.00K | -647.00K | -1.50M | 123.35M | -172.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -664.00K | -3.60M | -2.82M | 21.40M | -11.41M |